The Patient Bomb: Sustained Viral Response after Hepatitis C in Cirrhosis.
作者信息
Tato Marinho Rui António Rocha
机构信息
Serviço de Gastrenterologia e Hepatologia, Lisbon, Portugal.
出版信息
GE Port J Gastroenterol. 2020 Apr;27(3):147-148. doi: 10.1159/000504718. Epub 2020 Feb 5.
Abstract
摘要
相似文献
1
The Patient Bomb: Sustained Viral Response after Hepatitis C in Cirrhosis.
GE Port J Gastroenterol. 2020 Apr;27(3):147-148. doi: 10.1159/000504718. Epub 2020 Feb 5.
2
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
Liver Int. 2018 Mar;38(3):443-450. doi: 10.1111/liv.13534. Epub 2017 Oct 22.
3
An unfortunate failure: multifocal hepatocellular carcinoma in a non-cirrhotic patient with chronic hepatitis C treated with ledipasvir/sofosbuvir.
J Community Hosp Intern Med Perspect. 2018 Jun 12;8(3):167-169. doi: 10.1080/20009666.2018.1473702. eCollection 2018.
4
Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study.
Arab J Gastroenterol. 2021 Mar;22(1):23-27. doi: 10.1016/j.ajg.2020.09.001. Epub 2020 Nov 19.
5
Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.
Perm J. 2017;21:16-096. doi: 10.7812/TPP/16-096.
6
Hepatocellular carcinoma in a hepatitis C patient with sustained viral response and no fibrosis.
Ann Hepatol. 2009 Jan-Mar;8(1):64-7.
7
[Effectiveness and safety of sofosbuvir/velpatasvir combination ± ribavirin in the treatment of Chinese adults with chronic hepatitis C virus infection].
Zhonghua Gan Zang Bing Za Zhi. 2020 Oct 20;28(10):831-837. doi: 10.3760/cma.j.cn501113-20200831-00486.
8
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
J Hepatol. 2023 Feb;78(2):281-292. doi: 10.1016/j.jhep.2022.09.019. Epub 2022 Oct 5.
9
Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.
Exp Clin Transplant. 2017 Jun;15(3):314-319. doi: 10.6002/ect.2015.0289. Epub 2016 Feb 26.
10
Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis.
Intern Med. 2021;60(5):745-750. doi: 10.2169/internalmedicine.6029-20. Epub 2021 Mar 1.
引用本文的文献
1
HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development.
Cancers (Basel). 2021 May 19;13(10):2485. doi: 10.3390/cancers13102485.
本文引用的文献
1
Long-Term Follow-Up of Advanced Liver Disease after Sustained Virological Response to Treatment of Hepatitis C with Direct-Acting Antivirals: Outcomes from a Real-World Portuguese Cohort.
GE Port J Gastroenterol. 2020 Apr;27(3):149-159. doi: 10.1159/000503074. Epub 2019 Oct 10.
2
Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
Gastroenterology. 2019 Nov;157(5):1264-1278.e4. doi: 10.1053/j.gastro.2019.07.033. Epub 2019 Jul 26.
3
Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response.
J Viral Hepat. 2019 Nov;26(11):1257-1265. doi: 10.1111/jvh.13167. Epub 2019 Jul 17.
4
Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents.
Hepatology. 2020 Jan;71(1):44-55. doi: 10.1002/hep.30823. Epub 2019 Aug 19.
5
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6.
6
Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma.
Abdom Radiol (NY). 2016 Jan;41(1):71-90. doi: 10.1007/s00261-015-0592-8.
7
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
N Engl J Med. 2014 Apr 24;370(17):1604-14. doi: 10.1056/NEJMoa1401561. Epub 2014 Apr 10.
8
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
JAMA. 2012 Dec 26;308(24):2584-93. doi: 10.1001/jama.2012.144878.
9
Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.
Gastroenterology. 2011 Jun;140(7):1970-9, 1979.e1-3. doi: 10.1053/j.gastro.2011.02.058. Epub 2011 Mar 2.
10
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus.
Hepatology. 2008 Jun;47(6):1856-62. doi: 10.1002/hep.22251.
Zotero 插件